Navigation Links
Insmed to Host 2012 Second Quarter Earnings Conference Call
Date:7/24/2012

MONMOUTH JUNCTION, N.J., July 24, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, will host a conference call on Tuesday, August 7th, 2012, at 8:30 AM ET, to discuss its financial results for the second quarter of 2012.  Insmed intends to issue its quarterly financial results press release before the market opens on August 7th.

To participate in the live conference call, please dial 800-299-7089 (U.S. callers) or 617-801-9714 (international), and provide passcode 17092264.  A live webcast of the call will also be available at http://www.media-server.com/m/p/uk852bf4.  Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 10:30 AM ET on August 7th, at 888-286-8010 (U.S. callers) or 617-801-6888 (international), using passcode 11016101.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases.  Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced liposomal pulmonary technology in areas of high unmet need.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to our financial position, our estimates regarding our capital requirements and ou
'/>"/>

SOURCE Insmed Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Insmed To Present At JMP Securities 7th Annual Healthcare Conference
2. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACEĀ® In Patients With Non-tuberculous Mycobacterial Lung Disease
3. Insmed Announces First Quarter 2012 Financial Results
4. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACEĀ® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
5. Insmed to Host 2012 First Quarter Earnings Conference Call
6. MAP Pharmaceuticals Reports Second Quarter of 2012 Financial Results
7. Lexicon to Provide Second Quarter 2012 Financial Results
8. Onyx Pharmaceuticals To Report Second Quarter 2012 Financial Results After Market On August 1, 2012
9. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
10. InterMune Reports Second Quarter 2012 Financial Results and Business Highlights
11. Webcast Alert: Isis Pharmaceuticals Second Quarter 2012 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today reported ... Arena reported a lower net loss allocable to common stockholders in ... share, compared to a net loss allocable to common stockholders in ... share, and a net loss allocable to common stockholders in the ...
... TessArae® LLC, a global leader in resequencing microarray-based ... solutions for genetic testing of the mutations that ... TessArae,s expertise in microarray-based resequencing with novel nucleotide ... for all targeted mutations in multiple genes of ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9TessArae Delivers Lower Cost Option to Genetic Testing Market 2
(Date:4/24/2014)... three survivors of critical illness, according to a ... Medicine , and the majority of patients experience ... is one of the largest studies to investigate ... care survivors, according to lead author James Jackson, ... a significant public health issue, with roughly 5 ...
(Date:4/24/2014)... first in the world to discover a gene mutation ... , Ameloblastoma is an odontogenic tumour with a high ... found in the posterior of the lower jaw. Ameoloblastomas ... in the jaws as well as loss of several ... for surgery and the recurrence of ameloblastoma, but finding ...
(Date:4/24/2014)... State University researcher has found a relationship between motor ... autism spectrum disorder in very young children. , ... show a direct relationship between motor skills and autism ... skills should be included in treatment plans for young ... in OSU,s College of Public Health and Human Sciences. ...
(Date:4/24/2014)... 2009 the influenza pH1N1 virus caused the first flu ... in May 2009 and killed more than 50 people ... Finns mainly during flu epidemics (winter/spring seasons). , ... serious complicated illnesses. World Health Organization has recommended Tamiflu ... The disadvantage of this drug is that it targets ...
(Date:4/23/2014)... A pilot study by Massachusetts General Hospital (MGH) investigators ... unusual treatment for a serious medical problem use ... diarrhea caused by the Clostridium difficile ( ... published online in the journal Clinical Infectious Diseases ... fecal material from donors unrelated to patients was as ...
Breaking Medicine News(10 mins):Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3
... a global,provider of products and services that improve the ... for the medical technology company that will,be formed through ... , The new company will ... the company will offer to improve the safety and ...
... The DRE VSE Series includes a variety of affordable, dependable surgery ... ... (Vocus) February 16, 2009 -- DRE Veterinary — a ... VSE Series, a line of surgical and exam tables. All DRE ...
... (February 15, 2009)P&G Beauty & Grooming scientists are presenting ... that offers evidence of science,s role in evolving beauty ... observes the 200th anniversary of Charles Darwin,s birth, affording ... advanced science and technology to help individuals feel and ...
... re-newed demand for affordable drug rehabs - Mountainside Drug Rehab Center ... an inpatient substance abuse treatment curriculum that has been replicated by ... ... (PRWEB) February 15, 2009 -- The economy has been under extraordinary ...
... ROCK HILL, S.C., Feb. 14 A York County jury ... child who suffered a brain injury at birth. The award ... at fault when it assigned a nurse trainee to monitor ... with nausea and vomiting. The nurse misread fetal heart monitoring ...
... males face higher risk of fathering children with medical problems, ... wasn,t all that long ago that any suggestion that a ... father children sooner rather than later, would have been given ... of evidence suggests that as men get older, fertility can ...
Cached Medicine News:Health News:Cardinal Health Announces New Name for Spinoff Company 2Health News:Cardinal Health Announces New Name for Spinoff Company 3Health News:Cardinal Health Announces New Name for Spinoff Company 4Health News:DRE Veterinary Unveils Line of Surgical and Exam Tables 2Health News:DRE Veterinary Unveils Line of Surgical and Exam Tables 3Health News:DRE Veterinary Unveils Line of Surgical and Exam Tables 4Health News:Beauty and grooming science evolves 2Health News:Beauty and grooming science evolves 3Health News:Drug Rehab Mountainside Treatment Center is an Effective and Quality Option for Those Seeking Drug Treatment - Located Close to NY MA 2Health News:Men Must Contend With a Biological Clock, Too 2Health News:Men Must Contend With a Biological Clock, Too 3
These simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in hospitals....
... Anti-HTLV Mixed Titer Performance Panel consists of ... to strong positive for antibodies to HTLV ... for use by manufacturers and diagnostic laboratories ... data from all major test systems are ...
Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
The Repliform Tissue Regeneration Matrix is an acellular human dermal allograft that when surgically implanted is intended to function as a template, facilitating the body's fibroblasts to regenerate...
Medicine Products: